Animal Component-Free Cell Dissociation Kit is optimized for dissociation and passaging of human stem and progenitor cells cultured in various media formulations. Animal Component-Free Cell Dissociation Kit includes ACF Enzymatic Dissociation Solution and ACF Enzyme Inhibition Solution.
This kit was previously named MesenCult™-ACF Dissociation Kit. The name was changed to accommodate the use of this product with other cell types.
• Animal component-free solutions optimized for the dissociation and passaging of human stem and progenitor cells
Products for Your Mesenchymal Stromal Cell Research
Derive, Expand, and Differentiate Human Skeletal Muscle Progenitor Cells
Drug Screening and Phenotypic Analysis in a Microwell-based 3D Cell Culture System
Isolation of Umbilical Cord Mesenchymal Stromal Cells Using Explant Method
3D Modeling of Skeletal Muscle for In Vitro Functional Assaying
The Impact of Ancillary Materials on Your Translational Research
Mesenchymal Stromal Cells: Markers, Isolation and Culture, Differentiation, and Therapeutic Potential
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Direct cell-cell contact between haematopoietic progenitor cells (HPCs) and their cellular microenvironment is essential to maintain 'stemness'. In cancer biology, focal adhesion (FA) proteins are involved in survival signal transduction in a wide variety of human tumours. To define the role of FA proteins in the haematopoietic microenvironment of myelodysplastic syndromes (MDS), CD73-positive mesenchymal stromal cells (MSCs) were immunostained for paxillin, pFAK [Y(397)], and HSP90α/β and p130CAS, and analysed for reactivity, intensity and cellular localisation. Immunofluorescence microscopy allowed us to identify qualitative and quantitative differences, and subcellular localisation analysis revealed that in pathological MSCs, paxillin, pFAK [Y(397)], and HSP90α/β formed nuclear molecular complexes. Increased expression of paxillin, pFAK [Y(397)], and HSP90α/β and enhanced nuclear co-localisation of these proteins correlated with a consistent proliferative advantage in MSCs from patients with refractory anaemia with excess blasts (RAEB) and negatively impacted clonogenicity of HPCs. These results suggest that signalling via FA proteins could be implicated in HPC-MSC interactions. Further, because FAK is an HSP90α/β client protein, these results suggest the utility of HSP90α/β inhibition as a target for adjuvant therapy for myelodysplasia.
Cytotherapy 2006 JAN
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.
Dominici M et al.
The considerable therapeutic potential of human multipotent mesenchymal stromal cells (MSC) has generated markedly increasing interest in a wide variety of biomedical disciplines. However, investigators report studies of MSC using different methods of isolation and expansion, and different approaches to characterizing the cells. Thus it is increasingly difficult to compare and contrast study outcomes, which hinders progress in the field. To begin to address this issue, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. First, MSC must be plastic-adherent when maintained in standard culture conditions. Second, MSC must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. While these criteria will probably require modification as new knowledge unfolds, we believe this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
Contact STEMCELL Technologies
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not
share your email address with third parties. StemCell Technologies Inc. will use your email address to
confirm your identity and send you newsletters, transaction-related emails, promotional and customer
your email preferences at any time.